Kite partners with epigenetic editing startup Epic Bio in CAR-T work

Kite, the Gilead subsidiary specializing in CAR-T, is trying out epigenetic editing as it seeks new ways to create next-generation cell therapies that are more effective against cancer.

Teaming up with California-based Epic Bio, Kite will tap its new partner’s technology to engineer T cells by tinkering with gene expression…
Click here to view original post